[Clinical Effects of Pomalidomide-Based Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-04-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.02.017

Man Yang, Yan Huang, Ling-Xiu Zhang, Guo-Qing Lyu, Lu-Yao Zhu, Xian-Kai Liu, Yan Guo

{"title":"[Clinical Effects of Pomalidomide-Based Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma].","authors":"Man Yang, Yan Huang, Ling-Xiu Zhang, Guo-Qing Lyu, Lu-Yao Zhu, Xian-Kai Liu, Yan Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.017","DOIUrl":null,"url":null,"abstract":"Objective: To study the clinical effects of pomalidomide-based regimen in the treatment of relapsed and refractory multiple myeloma (RRMM).Methods: 60 patients with RRMM in hematology department of the First Affiliated Hospital of Xinxiang Medical University from November 2020 to January 2023 were selected. Among them, 15 cases were treated with PDD regimen (pomalidomide + daratumumab + dexamethasone), and 45 cases were treated with PCD regimen (pomalidomide + cyclophosphamide + dexamethasone). The clinical effects were evaluated.Results: The median number of treatment cycles for the entire cohort was 5 (2-11), with an overall response rate (ORR) of 75.0%. The ORR of patients treated with PDD regimen was 73.3%, while the ORR of patients treated with PCD regimen was 75.6%. The ORR of 46 patients with non high-risk cytogenetic abnormalities (non-HRCA) was 86.9%, significantly higher than the 35.7% of 14 patients with HRCA (χ2 =15.031, P < 0.05). The median PFS for all patients was 8.0(95%CI : 6.8-9.1) months and the median OS was 14.0 (95%CI : 11.3-16.7) months. Among patients treated with PDD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 7.0(95%CI : 4.6-9.3) months vs 4.0(95%CI : 3.1-4.8) months, χ2 =5.120, P < 0.05; OS: not reached vs 6.0(95%CI : 1.1-10.9) months, χ2 =9.870, P < 0.05]. Among patients treated with PCD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 9.0(95%CI : 6.2-11.8) months vs 6.0(95%CI : 5.4-6.6) months, χ2=14.396, P < 0.05; OS: not reached vs 11.0(95%CI : 6.4-15.6) months, χ2 =7.471, P < 0.05].Conclusion: The pomalidomide-based regimen has a good clinical effect and safety in the treatment of RRMM.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"431-436"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the clinical effects of pomalidomide-based regimen in the treatment of relapsed and refractory multiple myeloma (RRMM).

Methods: 60 patients with RRMM in hematology department of the First Affiliated Hospital of Xinxiang Medical University from November 2020 to January 2023 were selected. Among them, 15 cases were treated with PDD regimen (pomalidomide + daratumumab + dexamethasone), and 45 cases were treated with PCD regimen (pomalidomide + cyclophosphamide + dexamethasone). The clinical effects were evaluated.

Results: The median number of treatment cycles for the entire cohort was 5 (2-11), with an overall response rate (ORR) of 75.0%. The ORR of patients treated with PDD regimen was 73.3%, while the ORR of patients treated with PCD regimen was 75.6%. The ORR of 46 patients with non high-risk cytogenetic abnormalities (non-HRCA) was 86.9%, significantly higher than the 35.7% of 14 patients with HRCA (χ² =15.031, P < 0.05). The median PFS for all patients was 8.0(95%CI : 6.8-9.1) months and the median OS was 14.0 (95%CI : 11.3-16.7) months. Among patients treated with PDD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 7.0(95%CI : 4.6-9.3) months vs 4.0(95%CI : 3.1-4.8) months, χ² =5.120, P < 0.05; OS: not reached vs 6.0(95%CI : 1.1-10.9) months, χ² =9.870, P < 0.05]. Among patients treated with PCD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 9.0(95%CI : 6.2-11.8) months vs 6.0(95%CI : 5.4-6.6) months, χ²=14.396, P < 0.05; OS: not reached vs 11.0(95%CI : 6.4-15.6) months, χ² =7.471, P < 0.05].

Conclusion: The pomalidomide-based regimen has a good clinical effect and safety in the treatment of RRMM.

查看原文本刊更多论文

以泊马度胺为基础的方案治疗复发难治性多发性骨髓瘤的临床疗效

目的：探讨以泊马度胺为基础的方案治疗复发难治性多发性骨髓瘤（RRMM）的临床疗效。方法：选取2020年11月~ 2023年1月新乡医科大学第一附属医院血液科收治的RRMM患者60例。其中，15例采用PDD方案（泊马度胺+达拉单抗+地塞米松），45例采用PCD方案（泊马度胺+环磷酰胺+地塞米松）。评价两组的临床效果。结果：整个队列的中位治疗周期数为5(2-11)，总缓解率（ORR）为75.0%。PDD方案患者的ORR为73.3%，PCD方案患者的ORR为75.6%。46例非高危细胞遗传学异常（non-HRCA）患者的ORR为86.9%，显著高于14例HRCA患者的35.7% （χ2 =15.031, P < 0.05）。所有患者的中位PFS为8.0（95%CI: 6.8-9.1）个月，中位OS为14.0 （95%CI: 11.3-16.7）个月。在PDD方案治疗的患者中，非HRCA患者的PFS和OS显著高于HRCA患者[PFS: 7.0（95%CI: 4.6 ~ 9.3）个月vs 4.0（95%CI: 3.1 ~ 4.8）个月，χ2 =5.120, P < 0.05；OS：未达到vs 6.0（95%CI: 1.1 ~ 10.9）个月，χ2 =9.870, P < 0.05)。在PCD方案治疗的患者中，非HRCA患者的PFS和OS显著高于HRCA患者[PFS: 9.0（95%CI: 6.2 ~ 11.8）个月vs 6.0（95%CI: 5.4 ~ 6.6）个月，χ2=14.396, P < 0.05；OS：未达到vs 11.0（95%CI: 6.4 ~ 15.6）个月，χ2 =7.471, P < 0.05)。结论：以泊马度胺为基础的方案治疗RRMM具有良好的临床效果和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊